Q-omics provides the consensus-scored TOLLIP profile across patient tissues and cancer cell-line models. TOLLIP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TOLLIP is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, TOLLIP protein abundance shows 36,655 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where TOLLIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOLLIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOLLIP survival associations across molecular data types. TOLLIP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOLLIP RNA expression–survival associations across cancer types. High TOLLIP expression shows unfavorable associations in LUSC and HNSC, but favorable associations in KIRC, KIRP, SARC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TOLLIP RNA expression.
This table summarizes TOLLIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TOLLIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOLLIP shows lower tumor expression in LUAD, KIRP, THCA and UCEC and higher tumor expression in LIHC and COAD. The LUAD box plot shows higher TOLLIP RNA expression in normal versus tumor tissue (log2 FC = −0.493, t-test p < 0.001).
This table shows molecular features associated with TOLLIP in patient tissues and cancer cell lines. In patient samples, TOLLIP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TOLLIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
